Effect of long-acting insulin analogs on the risk of cancer: A systematic review of observational studies

Diabetes Care

Volumn 39, Issue 3, 2016, Pages 486-494

  Wu, Jennifer W ^a,b   Filion, Kristian B ^a,b   Azoulay, Laurent ^a,b   Doll, Margaret K ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; AGED; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETES MELLITUS; FEMALE; MALE; MIDDLE AGED; NEOPLASM; RISK FACTOR;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS;

EID: 84962097583     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1816     Document Type: Review

References (54)

1. Canadian Diabetes Association. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013; 37(Suppl. 1):1-227
2. National Institute for Health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes [article online], 2014. Available from http://www.nice.org.uk/guidance/cg87. Accessed 1 August 2015
3. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
4. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 2010;53:2667-2675
5. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765
6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
7. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
8. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-1754
9. Gale EA. Insulin glargine and cancer: another side to the story? Lancet 2009;374:521
10. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer-an unsubstantiated allegation. Diabetes Technol Ther 2009;11:473-476
11. Hernández-Díaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010;53: 802-808
12. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-513
13. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708
14. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55:644-653
15. Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism 2011;60:1379-1385
16. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS One 2011;6:e21368
17. Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases. Diabetes Care 2013;36:294-301
18. Grimaldi-Bensouda L, Cameron D, Marty M, et al.; ISICA Group. Risk of breast cancer by individual insulin use: an international multicen-ter study. Diabetes Care 2014;37:134-143
19. HabelLA, Danforth KN, Quesenberry CP,etal. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 2013;36:3953-3960
20. Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012;6:53-59
21. Ljung R,Talbäck M,Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies -a three-year population-based observation. Acta Oncol 2011;50:685-693
22. Mannucci E,Monami M, Balzi D, etal. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
23. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971
24. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55:51-62
25. Simó R, Plana-Ripoll O, Puente D, et al. Impact of glucose-lowering agents on the risk of cancer intype 2diabetic patients.The Barcelona case-control study. PLoS One 2013;8:e79968
26. Stürmer T, Marquis MA, Zhou H, et al. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care 2013;36:3517-3525
27. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetolo-gia 2011;54:2254-2262
28. van StaaTP,Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665
29. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673
30. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009;52:2507-2512
31. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52: 2499-2506
32. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-1973
33. Bordeleau L, Yakubovich N, Dagenais GR, et al.; ORIGIN Trial Investigators. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dys-glycemia. Diabetes Care 2014;37:1360-1366
34. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab 2012;38:485-506
35. Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One 2012;7:e51814
36. Du X, Zhang R, Xue Y, et al. Insulin glargine and risk of cancer: a meta-analysis. Int J Biol Markers 2012;27:e241-e246
37. Bronsveld HK, ter Braak B, Karlstad Ø, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 2015;17:100
38. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100
39. Scottish Intelligence Guidelines Network (SIGN). Search Filters [article online], 2014. Available from http://www.sign.ac.uk/methodology/filters.html. Accessed 16 January 2015
40. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087
41. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499
42. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
43. Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: statins and lung cancer. Epidemiology 2011;22:228-231
44. Tamim H, Monfared AA, LeLorier J. Application of lag-timeinto exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007;16:250-258
45. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-2271
46. Stroup DF,Berlin JA, Morton SC, etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012
47. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010; 58:783-787
48. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-1235
49. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocar-dial infarction. N Engl J Med 1998;339:229-234
50. Centers for Disease Control and Prevention (CDC) (Ed.). National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, 2014
51. U.S. Food and Drug Administration. Early Communication About Safety of Lantus (insulin glargine) [article online], 2009. Available from http://www.fda.gov/drugs/drugsafety/postmark etdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/ucm169722.htm. Accessed 13 December 2013
52. FDA Drug Safety Communication. Update to ongoing safety review of Lantus (insulin glar-gine) and possible risk of cancer [article online], 2011. Available from http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm. Accessed 13 December 2013
53. FDA Drug Safety Podcast for Healthcare Professionals. Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer [article online], 2013. Available from http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm240508.htm. Accessed 13 December 2013
54. European Medicines Agency. Outcome of review of new safety data on insulin glargine [article online], 2013. Available from http://www .ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2013/05/WC500143823.pdf. Accessed 13 December 2013